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*Corresponding author 
Abstract: Bromodomains bind to acetylated lysine residues on 
histone tails and other proteins. These recognition motifs act with 
other chromatin associated factors to modulate regulation of gene 
expression. The Bromodomain and Extra Terminal (BET) family of 
bromodomains have been the focus of extensive research, leading 
to the development of many potent, selective chemical probes and 
recently clinical assets. The profound biology associated with BET 
bromodomain inhibition has provided a convincing rationale for 
targeting bromodomains for the treatment of disease. However, the 
BET family represents just 8 of the 56 human bromodomains 
identified to date. Until recently, there has been significantly less 
interest in non-BET bromodomains, leaving a vast area of research 
and the majority of this new target class yet to be thoroughly 
investigated. It has been widely reported that several non-BET 
bromodomain containing proteins are associated with various 
diseases including cancer and HIV. Therefore, the development of 
chemical probes for non-BET bromodomains will facilitate 
elucidation of their precise biological roles and potentially lead to the 
development of new medicines. This review summarises the 
progress made towards the development of non-BET bromodomain 
chemical probes to date. In addition, we highlight the potential for 
future work in this new and exciting area. 
1. Introduction 
Epigenetics describes stable changes in gene expression 
caused by mechanisms other than those facilitated by alteration 
to the DNA sequence.[1] Such changes include post-translational 
modifications (PTMs) of histones, the packaging elements 
around which DNA is bound. A combination of PTMs creates the 
µKLVWRQH FRGH¶ DQG GLUHFWO\ LQIOXHQFHV FKURPDWLQ VWUXFWXUH
access and responses to this information, and therefore, 
precisely modulates gene expression.[2] Acetylation of lysine 
residues is one of the most extensively studied modifications of 
histone tails, regulated by the activity of histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), 
ZKLFK µZULWHµ DQG µHUDVH¶ WKH DFHW\O PDUNV UHVSHFWLYHO\
%URPRGRPDLQ µUHDGHU¶ PRGXOHV VHOHFWLYHO\ UHFRJQLVH DFHW\O-
lysine (KAc) residues in a context sensitive manner and in doing 
so, recruit the cellular transcriptional machinery to a certain 
histone mark. As such, bromodomains act together with other 
chromatin factors to modulate regulation of gene 
transcription.[3,4] 
Bromodomains are structurally conserved protein modules 
consiVWLQJ RI  Į-helices, linked by two flexible loop regions, 
which form the KAc binding site (Figure 1). In typical 
bromodomains, there are two interactions responsible for KAc 
recognition: a hydrogen-bond between the carbonyl moiety of 
KAc and the NH2 of an Asn; and a water mediated interaction to 
the hydroxyl group of a Tyr.[5] When developing synthetic ligands 
for bromodomains, it is these interactions that are typically 
competitively mimicked. 
 
 
 
 
 
Figure 1. X-ray crystallography of BRD4(1) in complex with histone H4(1-
12)K5/8Ac peptide (PDB code = 3UVW). Hydrogen bonds are shown as grey 
dashed lines and water molecules as red spheres. 
Bromodomains exist as part of bromodomain containing 
proteins (BCPs), which often contain other domains such as 
HATs and HDACs. BCPs typically operate as members of larger 
protein complexes, for example, BRD9 is found as part of the 
chromatin remodelling SNF/SWI BAF complex.[6] Therefore, the 
removal of the entire protein by knock-down experiments is a 
blunt and often misleading tool to investigate protein function. 
The use of chemical probes, which inhibit a single domain within 
a protein could show different relevant effects.[7,8] Therefore, 
inhibition of bromodomains by chemical probes allows their 
precise biological roles to be determined and validated in the 
context of disease. 
In humans there are at least 56 bromodomains found 
within 42 BCPs. Each bromodomain has been classified into one 
of 8 subgroups according to its sequence homology (Figure 
2).[1,9,10] There has been significant interest in the Bromodomain 
and Extra Terminal (BET) family of BCPs (BRD2, BRD3, BRD4 
and BRDT), leading to the development of several potent and 
selective chemical probes. The first chemical probes identified 
for this class of proteins were structurally related I-BET762 
(1a)[11,12,13] and (+)-JQ1 (2a)[14,15] in 2010. These compounds 
allowed exploration of BET bromodomain biology, driving an 
explosion of interest in this area. Importantly, there are negative 
control compounds reported for both I-BET762 (1a) and (+)-JQ1 
(2a) (1b and 2b respectively) , which have enabled phenotypic 
screening studies.[7,14] Following the disclosure of I-BET762 (1a) 
and (+)-JQ1 (2a), several other BET bromodomain chemical 
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probes have been identified including: I-BET151 (3),[16,17,18] PFI-1 
(4),[19] OX BD 02 (5),[20,21] MS436 (6)[22] and RVX-208 (7)[23] 
[Figure 3, to aid visualisation of the binding mode, all 
bromodomain inhibitors in this review display the KAc mimetic 
(where known) in the top left hand corner]. Inhibitors of the BET 
family have shown profound anti-cancer and anti-inflammatory 
properties, with some compounds entering clinical trials. 
Importantly, the chemical probes reported are from a structurally 
diverse set of chemotypes, building confidence that the common 
biological phenotypes observed are driven by BET 
bromodomain inhibition. As such, inhibition of the BET family of 
bromodomains has provided a convincing rationale for targeting 
bromodomains for the treatment of disease.[24]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Human bromodomain phylogenetic tree.  
2. Non-BET bromodomain inhibitors 
Despite the important advances within the BET family, the 
therapeutic potential of the remaining 48 bromodomains is 
relatively less explored. The development of non-BET 
bromodomain chemical probes will allow the community to gain 
a better understanding of their biology and potentially, help to 
identify and validate new targets for drug discovery.[3] In recent 
years, there has been significant progress towards this goal, 
with influential contributions from academic and industrial 
laboratories as well as the public-private partnership, the 
Structural Genomics Consortium (SGC). This has resulted in a 
growing number of chemical probes for non-BET bromodomains, 
highlighting the intense interest in this area of epigenetic 
research. 
2.1. Multi-bromodomain inhibitors 
It remains unclear whether multi-bromodomain 
pharmacology or more selective inhibition is necessary to deliver 
a relevant phenotype within the context of human disease. The 
development of both selective and multi-bromodomain inhibitors 
will help to answer this question. Towards this goal, the SGC 
and their collaborators have reported a series of multi-
bromodomain inhibitors. 
Bromosporine (8)[25] is a non-selective bromodomain ligand 
(Figure 4). Although the details of the development of 8 are yet 
to be published, the SGC website provides thermal shift data: at 
10 µM, ǻ7m  3.0 °C for the bromodomains of the BET family, 
CECR2, TAF1(2), BRD9 and CREBBP. Bromosporine (8), 
together with structurally related compound 9,[26] are unsuitable 
as chemical probes for a single bromodomain, due to their 
polybromodomain pharmacology. However, compounds 8 and 9 
may be enabling as start points towards chemical probes as well 
as for use in assay development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Chemical structures for selected BET bromodomain inhibitors.  
    
 
 
 
 
 
2.2. ATAD2 
The ATAD2 BCP is highly expressed in many diverse 
cancer types and expression levels have been strongly 
correlated with reduced patient survival and fast disease 
progression.[27] Although a chemical probe for ATAD2 could 
represent a useful start point for cancer therapy, the 
bromodomain has been reported as difficult to drug.[28] In order 
to target this challenging protein, Fesik and co-workers 
employed a fragment based screen conducted by NMR 
spectroscopy.[29] Several chemotypes were identified as novel 
bromodomain inhibitors, with compound 10 (Figure 4) being the 
most potent at ATAD2 (Kd: 350 µM). X-ray crystallography of 10 
in complex with the bromodomain of ATAD2 revealed that the 
triazole acts as the KAc mimetic.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Chemical structure for pan-bromodomain inhibitors 8 and 9 and 
ATAD2 fragments 10 and 11.  
Knapp and co-workers used a crystallographic fragment based 
screening approach to identify inhibitors of the ATAD2 
bromodomain.[30] Nine crystal structures were reported including 
that of thymidine (11), which represents a novel KAc mimetic. 
Compound 11 has an estimated Kd: 10 mM based on NMR 
titration experiments. Although the fragments reported exhibit 
weak binding affinities, these compounds may offer starting 
points for targeting the bromodomain for ATAD2, a previously 
un-drugged target. 
Most recently, GSK reported compound 12 as the first 
known micromolar inhibitor of ATAD2.[31] Identified from a 
fragment-based targeted array derived from a pan-bromodomain 
fragment, compound 12 shows IC50: 1.25 µM against ATAD2. 
Although this compound shows modest activity compared to the 
potency of some optimised BET inhibitors, this result is 
significant since ATAD2 is predicted to be one of the least 
tractable bromodomains.[28] As compound 12 is not selective 
over the BET family, it was progressed for further optimisation to 
deliver compound 13, which displays improved ATAD2 activity 
(IC50: 316 nM, TR-FRET) and >160 fold selectivity over the BET 
family.[32]. However, broader bromodomain profiling by means of 
BROMOscan[33] revealed that compound 13 is also active 
against the second bromodomains of TAF1 and TAF1L. The 
authors state that the optimisation of this series to generate a 
cell permeable and significantly more selective ATAD2 chemical 
probe will be the subject of their next publication.  
2.3. BAZ 
Homologous bromodomains BAZ2A/B belong to the BAZ 
family of proteins, which are ubiquitously expressed. Little is 
known about the biological roles of the BAZ family, therefore, the 
development of chemical probes will help to delineate their 
function. Despite BAZ2A/B BCPs having low predicted 
druggability,[28] multiple inhibitors of these domains have been 
reported. This perhaps highlights the tenacity of medicinal 
chemists in this area. Ciulli and co-workers describe a fragment 
based screening approach for the development of BAZ2B 
inhibitors.[34] From a library of 1300 compounds, 10 fragment hits 
were identified and subsequently crystallized in the 
bromodomain of BAZ2B. A tetrahydro-Ȗ-carboline fragment was 
the most potent and subsequently optimized to deliver 
compound 14 (Figure 5), which showed an IC50: 9 µM against 
BAZ2B (AlphaLISA). Importantly, this work demonstrated the 
druggability of the BAZ2B bromodomain for the first time.  
A collaboration between GSK and the SGC led to the 
development of GSK2801 (15a), the first selective chemical 
probe for BAZ2A/B.[35] Screening of the BAZ2A bromodomain 
against a set of molecules that contained KAc mimetics led to 
identification of the indolizine template, which had been 
previously reported as an inhibitor of BET bromodomains.[36] An 
iterative medicinal chemistry design strategy was employed to 
deliver GSK2801 (15a), which displays Kd: 257 and 136 nM 
(ITC) against BAZ2A and BAZ2B, respectively. Selectivity over 
46 bromodomains was assessed by thermal shift: at 10 ȝ015a 
showed a ǻ7m of 4.1 and 2.7 °C for BAZ2A and BAZ2B, 
respectively. Significant shifts were also observed for TAF1L(2) 
(3.4 °C) and BRD9 (2.3 °C). These data were supported by bio-
layer interferometry (BLI) experiments probing the interaction of 
GSK2801 (15a) against 40 bromodomains, at two 
concentrations (0.2 and 1  ȝ0No interaction was detected for 
the bromodomains of BRD4(1), CREBBP, TRIM24, PB1(5), 
PCAF or ATAD2, but in agreement with the thermal shift data, 
BRD9 and TAF1(L) were detected as the major off-targets. To 
    
 
 
 
 
 
test whether GSK2801 (15a), would bind to endogenous BAZ2 
proteins, a chemoproteomic competition binding assay was 
utilized. A linkable analogue of GSK2801 (15a), was immobilized 
on to a solid support and incubated with nuclear and chromatin 
enriched HuT78 extracts. Of the 18 endogenous full-length 
bromodomain proteins that bound to the immobilsed compound, 
only BAZ2A and BAZ2B displayed a dose-dependent reduction 
in the presence of GSK2801 (15a). Evidence of cellular target 
engagement was provided by a FRAP assay in which GSK2801 
(15a) displaced BAZ2A/B from chromatin in U2OS cells. In order 
to determine the suitability of GSK2801 (15a) as an in vivo tool, 
pharmacokinetic parameters were measured after 
intraperitoneal and oral dosing to male CD1 mice. GSK2801 
(15a) had reasonable in vivo exposure after oral dosing, modest 
clearance and plasma stability, which should allow the 
compound to be used as a BAZ2A/B bromodomain inhibitor in 
vivo. Importantly, this group also developed structurally similar 
negative control compound 15b. Compound 15b helped to 
inform chemoproteomics experiments, building confidence that 
any phenotype observed was not driven by off target activities.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Chemical structures for BAZ2A/B bromodomain inhibitors. 
More recently, the SGC have collaborated with the Institute 
of Cancer Research to develop BAZ2-ICR (16) as a chemical 
probe for BAZ2A/B [37] (Figure 5). BAZ2-ICR (16) was optimized 
from a single hit identified in a screen of putative bromodomain 
inhibitors. Compound 16 shows Kd: 109 and 170 nM against 
BAZ2A and BAZ2B, respectively (ITC). In agreement with the 
ITC data, BAZ2-ICR (16VKRZHGǻ7m: 5.2 and 3.8 °C for BAZ2A 
and BAZ2B, respectively, with no significant shifts against all 
RWKHU EURPRGRPDLQV H[FHSW &(&5 ǻ7m: 2.0 °C). ITC 
experiments revealed a Kd: 1.55 ȝ0DW&(&5showing 15-fold 
selectivity. Evidence of cellular target engagement was 
confirmed by means of a chromatin displacement FRAP assay 
in U2OS cells. In order to determine the suitability of BAZ2-ICR 
(16) as an in vivo tool compound, mouse pharmacokinetic data 
was obtained. The results from these experiments indicated that 
BAZ2-ICR (16) is suitable for use in vivo, with 70% bioavailability 
and moderate clearance (~50% of mouse liver blood flow) and 
volume of distribution.  
The chemical probes developed for BAZ2A/B represent an 
excellent toolset with which the biology can be fully investigated. 
Importantly, these chemical probes are structurally distinct, in 
vivo capable and a negative control GSK8573 (15a) is also 
available for cross validation studies.  
2.4. BRD9 
Until relatively recently there has been very little in the 
literature concerning the bromodomain of BRD9. However, 
BRD9 is reported as a component of the chromatin remodeling 
SNF/SWI BAF complex, which plays a role in regulation of gene 
expression, providing impetus to develop chemical probes.[6] 
The first inhibitor of BRD9 was reported by Ley and co-workers, 
who used flow chemistry to identify a series of compounds 
based on the structure of Bromosporine (8, Figure 4).[38] Initially, 
binding to BRD9 was assessed in flow by frontal affinity 
chromatography coupled with mass spectrometry. This allowed 
for rapid binding information, which was subsequently confirmed 
by thermal shift. Of the compound set tested, compound 17 
(Figure 6) showed the greatest thermal shift against BRD9 (ǻ7m: 
4.3 °C). However, ǻ7m was also seen for BRD4 (6.7 °C), BRPF1 
(5.4 °C), BRPF3 (3.1 °C), CECR2 (5.6 °C), CREBBP (4.3 °C), 
EP300 (8.0 °C), and TRIM24 (1.8 °C).  
Filippakopoulos and co-workers have reported the 2-
amine-9H-purine scaffold as a ligand for BRD9.[39] Through 
iterative structure based design, compound 17 was identified as  
a BRD9 inhibitor. 18 showed Kd: 0.28 µM against BRD9 (ITC), 
as well as some BRD4(1) activity (Kd: 1.4 µM). In order to 
understand the binding mode of the 2-amine-9H-purine scaffold, 
attempts were made to obtain an X-ray crystal structure of 18 in 
complex with the bromodomains of BRD9 and BRD4(1). 
Although these attempts were unsuccessful, X-ray 
crystallography of a structurally related analogue indicated 
occupation of the KAc binding site. Interestingly, the analogue 
was found to induce a structural rearrangement in the BRD9 
binding pocket, resulting in an unprecedented cavity shape. This 
induced fit could explain the greater BRD9 activity relative to 
BRD4(1) observed for this template. Docking studies suggest 
that 18 elicits the same structural rearrangement as observed for 
the analogue. Cellular target engagement for compound 18 was 
demonstrated using a NanoBRET assay,[40] in which 18 was 
found to displace BRD9 from chromatin with IC50: 477 nM. In 
addition, 18 is not cytotoxic up to concentrations of 33 µM. The 
9H-purine scaffold offers a template that can be used for further 
optimization to deliver tool molecules for the bromodomain of 
BRD9. 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Chemical structures for BRD9 inhibitors.  
GSK and the University of Strathclyde have reported I-
BRD9 (19), as a selective, cell penetrant chemical probe for 
BRD9.[41] The thienopyridone template was identified from a 
cross-screen of GSK compounds and was subsequently 
optimized through iterative structure-based design to deliver I-
BRD9 (19). The compound displays an IC50: 0.05 and 5 µM 
against BRD9 and BRD4(1), respectively, as determined by TR-
FRET assay. Broader bromodomain profiling was conducted by 
means of BROMOscan[33] in which I-BRD9 (19) was tested 
against a panel of 34 bromodomains. The results from this 
screen confirmed excellent BRD9 activity (Kd 1.9 nM), with >700 
fold selectivity over the BET family, >200 fold over the highly 
homologous BRD7 (Kd: 380 nM) and >70 fold over every other 
bromodomain tested. I-BRD9 (19) displaces chromatin from 
BRD9 in cells with an IC50: 160 nM, providing evidence of 
cellular target engagement. In addition, I-BRD9 (19) was found 
to bind to full length, endogenous BRD9 with a IC50: 80 nM and 
>625 fold selectivity over BET family member, BRD3.[42], [43] 
Selectivity beyond the bromodomain family was also assessed. 
I-BRD9 (19) was tested in a diverse panel of 49 targets including 
various enzymes, receptors and ion channels. No activity was 
observed at less than 5 µM, providing confidence in the 
selectivity of this probe molecule.  Subsequent cellular studies 
identified genes involved in oncology and immune response 
pathways that were selectively modulated by I-BRD9 (19).  
The SGC and the University of Oxford reported LP99 (20) 
as a BRD9/BRD7 chemical probe.[44] LP99 (20) was developed 
from a fragment exploiting chiral synthesis with diverse building 
blocks to deliver good BRD9 (Kd: 99 nM) and BRD7 (Kd: 
909 nM) activities, as determined by ITC. Broader selectivity 
was determined by thermal shift against a panel of 48 
bromodomains. LP99 (20) showed excellent selectivity, with 
<1 °C stabilization of all bromodomains except BRD9 and BRD7. 
Cellular target engagement was assessed by a NanoBRET 
assay, confirming the ability of LP99 (20) to disrupt binding of 
BRD9 and BRD7 to chromatin in cells. To investigate the effect 
of BRD9/7 inhibition on the expression of proinflammatory 
cytokines, a human THP-1 monocytic cell line was stimulated 
with lipopolysaccharide. LP99 (20) was found to inhibit 
production of interleukin 6 in a dose dependent manner.  
The SGC website also reports BI-9564 as a BRD9/7 
selective chemical probe, developed in collaboration with 
Boehringer Ingelheim.[45] This probe was discovered through 
fragment-based screening to deliver excellent activity (BRD9 
Kd : 14 nM; BRD7 Kd : 239 nM, ITC) and selectivity over the BET 
family of bromodomains (>100 µM by AlphaScreen). BI-9564 
shows off-target activity against CECR2 in vitro (Kd: 258 nM, 
ITC), but not in cells (at 1 µM, FRAP). The structure of BI-9564 
has not yet been reported.  
Most recently, the SGC and the University of Oxford report 
compound 21 as a BRD9/7 inhibitor.[46] Using BAZ2A/B chemical 
probe 15a (Figure 5) as a start point, 21 was developed by 
optimisation of the 1, 3 and 7-positions of the template. 
Compound 21 was potent at BRD9 (Kd: 68 nM) and BRD7 (Kd: 
368 nM), with good selectivity over BRD4(1) (Kd: 15 µM), as 
determined by ITC. Broader selectivity was assessed by thermal 
shift in which compound 21 showed ǻTm: 5.6 °C against BRD7, 
with weak affinity for the bromodomains of CBP, p300 and FALZ 
(ǻTm: 1.8, 2.0, and 1.1 °C respectively).  
Recent efforts towards the development of BRD9 chemical 
probes has resulted in the identification of several structurally 
orthogonal inhibitors. As a result of this, the downstream 
biological effects of BRD9 bromodomain inhibition can be 
investigated for the first time. Early studies with these probes 
suggest that BRD9 may play a role in both oncology and 
inflammation, and as such, provide impetus to further validate 
these findings.  
2.5. BRPF 
The BRPF family cosists of BRPF1B/2/3, which are 
important scaffolding proteins for the assembly of HAT 
complexes of the MOZ/MORF family of transcriptional 
coactivators. It is reported that translocations of MOZ are 
associated with aggressive subtypes of leukemia.[47] Chemical 
probes for the BRPF family of bromodomains have recently 
been disclosed on the SGC website. OF-1 (22) is a BRPF1B/2/3 
selective chemical probe, which displays Kd: 100 nM, 500 nM 
    
 
 
 
 
 
and 2.4 µM, respectively (Figure 7).[48] Selectivity against other 
bromodomains is, in general >100 fold. Importantly, the closest 
off-target bromodomain activity is against BRD4 (39 fold 
selectivity). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Chemical structures for BRPF family bromodomain inhibitors.  
GSK have reported a series of BRPF1B selective inhibitors, 
which share the same benzimidazolone core as OF-1 (22).[49] 
Lead compound 23a (Figure 7) was obtained by cross-screening 
analogues of a fragment hit identified in a BRD4 STD-NMR 
screen. 23a shows a IC50: 80 nM (TR-FRET) against BRPF1B, 
with 100 and >1000 fold selectivity over BRPF2 and BRPF3, 
respectively. Given this excellent activity and selectivity profile, 
broader bromodomain selectivity was assessed by means of 
BROMOscan.[33] In a panel of 35 phylogenetically diverse 
bromodomains, 23a showed a BRPF1B Kd: 7.9 nM, with 600 fold 
selectivity over the BET family. Critically, evidence of cellular 
target engagement was achieved using a cellular chromatin 
displacement assay in which 23a showed disruption of 
chromatin with a IC50: 1 µM. Importantly, this group report 
compound 23b as a structurally analogous negative control, 
which will facilitate biological investigations. Of particular note is 
that compound 23a is the first bromodomain inhibitor reported to 
be selective for a single bromodomain.  
PFI-4 (24) is another benzimidazolone compound reported 
as a selective inhibitor of BRPF1B.[50] Developed by the SGC in 
collaboration with Pfizer, PFI-4 (24) binds to selectively BRPF1B 
with Kd: 13 nM, as determined by ITC. Further details 
surrounding the development and broader selectivity profile of 
this compound have not yet been reported. 
NI-57 (25) is a BRPF family selective chemical probe 
developed by the SGC in collaboration with University College 
London.[51] As reported on the SGC website, NI-57 (25) binds to 
BRPF1B (Kd: 31 nM), BRPF2 (Kd: 108 nM) and BRPF3 (Kd: 
408 nM), with nanomolar affinity, as determined by ITC. NI-57 
(25) is very selective against the BET family and the closest off-
target effects are against BRD9 (32 fold selective).  
The number of chemical probes for the BRPF family 
emerging in the literature will allow significant advances towards 
target validation of non-BET bromodomains. However, the 
majority of chemical probes for which the structures have been 
reported share the same benzimidazolone core. In the future, 
biological validation experiments would benefit from BRPF1 
family chemical probes from a variety of structural scaffolds. 
2.6. CREBBP 
Outside of the BET family, much of the focus in chemical 
probe discovery has been with the structurally related 
bromodomains of CREBBP and EP300. This is most likely due 
to the fact that many unselective BET bromodomain binders also 
interact with the bromodomain of CREBBP, potentially indicating 
the high homology between these domains. Nevertheless, these 
unselective BET inhibitors have served as encouraging start 
points for the development of some selective CREBBP/EP300 
inhibitors. 
Research conducted by Zhou and co-workers led to the 
discovery that the CREBBP bromodomain binds to KAc382 of 
the human tumour suppressor, p53.[52] It is reported that this 
specific interaction is required for acetylation dependent 
coactivator recruitment after DNA damage. In order to develop 
small molecule binders of the CREBBP bromodomain, Zhou and 
coworkers aimed to inhibit the CREBBP-p53 interaction, initially 
reporting compounds MS2126 (26) and MS7972 (27) 
(Figure 8).[53]  
These small molecules were discovered by an NMR screen of a 
focused library of 200 compounds, which was constructed based 
on the structural knowledge of the CREBBP bromodomain-p53-
KAc382 3-component interaction. Special attention was paid to 
the KAc mimetic and electrostatics at the opening of the KAc 
binding channel, in order to drive selectivity over other 
bromodomains. As CREBBP is positively charged in this region, 
electron rich functional groups were included in the compound 
collection. Of the 200 compounds screened, 14 were identified 
to bind to the CREBBP bromodomain. Compounds MS2126 (26) 
and MS7972 (27) were found to block the CREBBP-p53 
interaction at concentrations of 100 and 50 µM, respectively. 
Furthermore, when tested in U2OS cells with doxorubicin-
stimulated DNA damage, 26 and 27 suppressed p53 levels, 
further strengthening the link between CREBBP bromodomain 
and p53 binding. These results demonstrate that small 
molecules can modulate p53 stability and function in response to 
DNA damage. MS7972 (27) showed a Kd: 20 µM against 
CREBBP, as determined by a fluorescence anisotropy (FA) 
assay.  
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Chemical structures for CREBBP bromodomain inhibitors. 
The same group has also reported conformationally 
restricted cyclic peptides as inhibitors of the CREBBP 
bromodomain.[54] Through rational design using molecular 
dynamics simulations on the NMR structure of the CREBBP 
bromodomain in complex with KAc382 of p53, a series of cyclic 
peptide inhibitors were identified. These molecules were found 
to bind to the bromodomain of CREBBP, with greater affinity 
than natural ligands including p53. Compound 28 was selected 
as the lead peptide, which shows a Kd: 8 µM (FP assay), 
representing a 24 fold improvement in affinity compared to the 
endogenous ligand. The selectivity of this peptide for CREBBP 
was confirmed by an FP assay, with no interaction observed for 
the bromodomains of PCAF and BRD4(1)/(2). Cell-based 
assays carried out in colorectal carcinoma HCT116 cells 
demonstrated the efficacy of 28 to modulate p53 stability and 
function in response to DNA damage. 
Subsequently, Zhou co-workers conducted an NMR 
screen of a diverse library of 3000 compounds, leading to the 
identification of the azobenzene moiety as a CREBBP 
bromodomain ligand.[55] Of the 3000 compounds tested, 10 hits 
were generated and optimized to deliver Ischemin (29). This 
molecule inhibits the CREBBP bromodomain-p53 interaction 
with an IC50: 5 µM, as determined by a cell-based assay. 
Selectivity over other bromodomains was investigated using a 
fluorescence displacement assay in which Ischemin (29) was up 
to 5-fold selective over the bromodomains of PCAF, BRD4(1) 
and BAZ2B. In cellular assays, Ischemin (29) alters PTMs of p53 
and histones, and inhibits the CREBBP-p53 interaction and 
transcriptional activity. 29 prevents apoptosis in ischemic 
cardiomyocytes, suggesting that inhibition of the CREBBP 
bromodomain or the other targets that bind to this compound 
with similar affinity may provide an effective treatment for 
diseases such as myocardial ischemia. 
These compounds demonstrate the utility of CREBBP 
bromodomain inhibitors for target validation and their potential to 
treat human disorders. Since these discoveries, there has been 
significant interest in the development of alternative 
CREBBP/EP300 inhibitors.  
I-CBP112 (30) is a chemical probe for the bromodomains 
of CREBBP and EP300, developed by GSK in collaboration with 
the SGC (Figure 8).[56] I-CBP112 (30) shows Kd: 151 and 625 nM 
against CREBBP and EP300, respectively (ITC). Selectivity over 
a range of bromodomains was established including ATAD2, 
BAZ2B, BRD2(2), BRD4(1), PB1(5), PCAF, PHIP(2) and 
TRIM24, as determined by BLI. Further ITC titrations confirmed 
good selectivity over the BET family (37 and 132 fold for BRD4 
BD1 and BD2 respectively). I-CBP112 (30) has been used to 
probe the biological function of CREBBP/EP300. In leukemia, I-
CBP112 (30) was found to impair the disease initiating self-
renewal leukemic cells in vitro and in vivo without causing 
significant toxicity. These studies further validate the role of 
CREBBP/EP300 in oncology and could potentially pave the way 
for future therapies. 
The 3,5-dimethylisoxazole fragment is a well-studied KAc 
mimetic, which features in a number of BET bromodomain 
inhibitors (see 3 and 5, Figure 3). However, some of these 
compounds show some activity against the CREBBP 
bromodomain, with compound 31 displaying an IC50 value of 
32 µM, as determined by AlphaScreen.[20] Although not selective 
over the BET family [BRD4(1) IC50: 51 µM; BRD2(1) IC50: 28 µM], 
compound 31 could be considered as a good start point for the 
development of more potent and selective ligands for CREBBP. 
Towards this goal, the SGC collaborated with the University of 
Oxford to deliver SGC-CBP30 (32).[57] SGC-CBP30 (32) shows 
Kd: 21 and 38 nM against CREBBP and EP300, respectively, as 
determined by ITC. In addition, compound 32 is 40 fold selective 
    
 
 
 
 
 
over BET family member, BRD4(1). Broader bromodomain 
selectivity was assessed by thermal shift, in which compound 32 
was tested against 10 targets. No ǻ7m above 2 °C was observed 
against any other bromodomains apart from BET family 
members BRD2(1), BRD3(1), and BRD4(1), with ǻ7m between 1 
and 2 °C. Cellular target engagement was determined using a 
FRAP assay, in which 32 was shown to disrupt CREBBP 
bromodomain-chromatin complex in HeLa cells. To investigate 
the effect of compound 32 on the CREBBP bromodomainíp53 
interaction in a cellular context, a luciferase reporter assay for 
p53 induction was used. Compound 32 inhibited doxorubicin 
induced p53 activity with an IC50: 1.5 ȝ0 ADME properties were 
determined for 32 LQRUGHUWRXQGHUVWDQGLW¶VXWLOLW\DVDn in vivo 
probe. In a human liver microsome stability assay, no compound 
was detected after 1 hour, suggesting rapid metabolism. 
Although 32 may not be suitable as an in vivo tool, this 
compound is likely to be valuable in understanding the biological 
function of both CREBBP and EP300 in vitro.  
Conway and coworkers reported compound 33 as a ligand 
for the CREBBP bromodomain.[58] 33 displays a Kd: 390 nM 
against CREBBP (ITC), with modest selectivity over BRD4(1) 
(Kd: 1.4 µM). A FRAP assay was used to evaluate 33 in a 
cellular setting. Compound 33 was found to displace the 
CREBBP bromodomain from chromatin in U2OS cells in a dose 
dependent manner. Although not selective over the BET family, 
33 is a valuable addition to the CREBBP tool set to help validate 
this protein as a target for the treament of disease.  
Most recently, Unzue and co-workers report the 
development of compound 34 as an inhibitor of CREBBP.[59] 
Ligand identification was conducted by fragment-based docking 
into the structure of the CREBBP bromodomain. Of the 17 
compounds initially selected for in vito validation, the acetyl 
benzene scaffold was selected for further investigation to deliver 
a series of CREBBP inhibitors. Compound 34 showed the best 
combination of potency and selectivity with a CREBBP Kd: 
2.0 µM and BRD4(1) Kd: >50 µM, as determined by ITC.  
The efforts towards chemical probe discovery for the 
bromodomains of CREBBP/EP300 have proved extremely 
useful to enable target validation within human disease. 
Importantly, these discoveries have provided a range of 
structurally distinct inhibitors, which address potential off target 
binding and build further confidence in the biological phenotypes 
observed.  
2.7. PCAF 
Zhou and co-workers were the first to report a small 
molecule ligand for a bromodomain, namely PCAF. This group 
showed that the bromodomain of PCAF binds specifically to 
KAc50 of the HIV-Tat protein complex, a critical interaction for 
viral replication.[60] Moving forward, NMR screening was used to 
discover small molecule inhibitors of this interaction. These 
efforts led to the discovery of several inhibitors including 
compound 35, which displays IC50: 1.6 µM against PCAF, as 
determined by a peptide competition assay (Figure 9). Despite 
efforts to optimise compound 35, no increase in potency was 
reported.[61] 
 
 
 
 
 
 
 
 
Figure 9. Chemical structure of PCAF inhibitor 35. 
2.8. SMARCA4 
SMARCA4 is part of the SNF/SWI complex, which plays a 
key role in chromatin remodelling and transcription control. Loss 
of function of SMARCA4 and components of SWI/SNF has been 
linked to cancer development.[62] Pfizer and the SGC have 
collaborated to develop PFI-3 (36), an inhibitor for the 
bromodomain of SMARCA4 (Figure 10).[63] This novel 
chemotype demonstrates Kd: 89 nM against SMARCA4, as well 
as 48 nM against the homologous PB1(5) bromodomain (ITC). 
Broader bromodomain selectivity was assessed by thermal shift 
with binding FRQILUPHG DW 60$5&$ ǻ7m: 5.1), SMARCA2 
ǻ7mDQG3% ǻ7m: 7.5). No interaction was observed 
with PB1(2±4), and there was no cross-reactivity in a panel of 36 
kinases.  
 
 
 
 
 
 
Figure 10. Chemical structure for SMARCA2/4, PB1(5) inhibitor, PFI-3 (36).[64]  
Interestingly, PFI-3 (36) has been used to probe the biological 
function of the SMARCA2/4 bromodomains. Although PFI-3 (36) 
is capable of displacing the SMARCA2 bromodomain from 
chromatin, demonstrating cellular target engagement, it fails to 
show the antiproliferative phenotype observed through SiRNA 
knock-down studies. Therefore, PFI-3 (36) has invalidated the 
SMARCA2 bromodomain, and instead, helped to identify the 
ATPase domain as the relevant therapeutic target. These 
studies further highlight the power of chemical probes for both 
target validation and in validation, particularly in combination 
with protein knock-down experiments.  
2.9. OTHERS 
There are a growing number of bromodomain inhibitors 
that are broadly selective, showing activity against a small 
number of bromodomains. Examples include compound 33, 
which shows activity against TAF1(2), TAF1L(2) and BRD4 
(Figure 11).[65] Bradner and coworkers used fluorous tagged 
multicomponent reactions to develop a library of 3,5-
dimethylisoxazole containing bromodomain inhibitors. 
Subsequent optimization of the scaffold delivered lead 
compound 37, which binds to BRD4(1) with a Kd: 550 nM as 
determined by ITC. Broader bromodomain screening by means 
    
 
 
 
 
 
of BROMOscan[33] confirmed binding to BRD4 (Kd: 80 nM) but 
revealed potent binding to TAF1(2) (Kd: 560 nM) and TAF1L(2) 
(Kd: 1.3 µM). Although the binding to TAF1(2) is relatively weak, 
this observation suggests a starting point for the development of 
a selective TAF1 bromodomain chemical probe. 
The SGC have reported benzimidazolone 38 as an 
inhibitor of BRPF1B/2 and TRIM24.[66] In order to develop a 
TRIM24 specific inhibitor, commercially available 1,3- 
benzimidazolones were screened using AlphaScreen technology. 
Several compounds were identified to be active against TRIM24 
but were also active against BRPF1B/2. Moving forward, the 5 
and 6-positions of the template were optimised to deliver 
compound 38, which shows a Kd: 222 nM and 137 nM against 
TRIM24 and BRPF1B respectively (ITC). The selectivity of 
compound 38 was evaluated using a thermal shift assay 
consisting of a panel of 45 bromodomains. Significant shifts 
were observed for BRPF1B/2 and TRIM24, supporting the ITC 
data generated. Cellular activity was determined using a FRAP 
assay in which 38 displaced full-length TRIM24 from chromatin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Chemical structures for bromodomain inhibitors 37, 38 and 39.  
Independently, Palmer and co-workers used a structure 
guided approach to develop compound 39 as a TRIM24 
inhibitor.[67] In order to develop a selective TRIM24 inhibitor, 
three hit identification approaches were explored: virtual in silico 
high-throughput screening (HTS), construction of a focused KAc 
mimetic library, and a traditional small molecule HTS. Three 
different chemotypes were indentified, with the same 
benzimidazolone template as compound 38 selected for further 
optimisation. SAR evaluation around this core provided IACS-
9571 (39), which is potent against the bromodomain of TRIM24 
[IC50: 7.6 nM, (AlphaScreen)]. Broader selectivity profiling was 
asessed by BROMOscan[33] in which 39 was tested against 32 
bromodomains. Results from this screen indicated off activity 
against the BRPF family. Subsequent dose-response 
determinations demonstrated 39 to be a dual TRIM24/BRPF1B 
inhibitor (Kd: 1.3/ 2.1 nM), with 9 and 21 fold selectivity over 
BRPF2 and BRPF3 respectively. Compound 39 does not 
interact with the bromodomains of the BET family, displaying 
greater than 7700 fold selectivity versus BRD4(1/2) relative to 
TRIM24. Pharmacokinetic parameters were determined for 39 in 
female CD1 mice after IV administartion of a 1 mg/kg dose. 
Moderate clearence (43 mL/min/kg) was observed and the 
terminal half life was 0.7 h. After oral dosing of 10mg/kg, 
bioavailability of 39 was 29%, suggesting that this molecule 
could be used for in vivo studies.  
Although selectivity over the BRPF family could not be 
achieved for both 38 and 39, these compounds might represent 
a good starting point towards the development of a selective 
TRIM24 inhibitor, which could serve as a valuable tool for 
understanding the biology of this bromodomain.  
3.0 Outlook 
The development of chemical probes for bromodomains 
represents an exciting area of research for both academic and 
industrial laboratories. Although much of the research has 
focused on the BET family, there have been significant 
advances outside of this subgroup. The identification of 
promising start points and in some cases potent and selective 
chemical probes by both academic and industrial laboratories 
has facilitated rapid progression in this field. Importantly, the 
majority of these probe molecules have been made available to 
the scientific community in an effort to elucidate the biological 
function of human bromodomains. In particular, the pioneering 
efforts of the SGC and their collaborators have led the way for 
both BET and non-BET chemical probe research programmes. 
There are now validated chemical probes or potential start 
points towards chemical probes for several of the main 
bromodomain families of the human phylogenetic tree. This 
represents a significant advancement in the field, allowing an 
understanding of the biology for a structurally diverse set of 
bromodomains. In the majority of cases, these chemical probes 
are selective for a particular branch of the phylogenetic tree, 
targeting at least two bromodomains. It is unknown whether 
multi-bromodomain pharmacology is necessary to observe a 
biological phenotype or if more selective bromodomain inhibition 
is required. Interestingly, multi-bromodomain activity is not 
always observed within the same family. During our own 
experience developing I-BRD9 (19) we observed binding to the 
bromodomain of CECR2 with next greatest affinity after BRD9, 
not BRD7 as expected. Therefore, small molecule off-target 
    
 
 
 
 
 
activities are not always predictable based on the sequence 
homology of the phylogenetic tree.  
Of the non-BET chemical probes discussed in this review, 
only GSK2801 (15a), BAZ-ICR (16) and IACS-9571 (39) are 
reported to be suitable for use as in vivo tools. It is not clear 
whether the other inhibitors reported would be suitable for in vivo 
experiments, which may highlight a limitation in the discoveries 
made to date. Therefore, future effort should be placed on the 
development of in vivo tools so that the community can fully 
understand the role of bromodomains in preclinical models, to 
provide further insight into their potential therapeutic utility in 
human disease. However, it is important to note that despite 
extensive effort, inhibition of non-BET bromodomains by 
chemical probes has yet to deliver a clear disease phenotype in 
the majority of cases. This perhaps highlights that the discovery 
of high quality chemical probes is only the first step on a difficult 
path towards a new class of therapeutics.  
Due to the importance of chemical probes for enabling 
target validation, it is critical that confidence in any phenotype 
observed is due to inhibition of the target protein. As such, the 
selectivity criteria for a chemical probe is arguably more 
demanding than that of a drug candidate.[7] However, it is always 
possible, and indeed likely that any chemical probe will possess 
off target activity. Therefore, we advocate the use of structurally 
similar negative control compounds as well as structurally 
distinct chemical probes to enable cross validation studies.[68] It 
is pleasing to see non-BET bromodomain chemical probes along 
with their biologically negative analogues emerging in the 
literature. 
There are a growing number of bromodomains for which 
there are multiple chemical probes from a diverse range of 
chemotypes. Examples include CREBBP, BAZ2A/B and BRD9, 
highlighting their tractability to small molecule binding. As a 
result, the epigenetic community is now in a better position than 
ever to fully investigate the therapeutic potential of these targets. 
In particular, the chemical probes developed for BAZ2A/B 
represent an excellent toolset to investigate the biology, which 
will facilitate validation of these bromodomains. These probes 
are in vivo capable, structurally orthogonal and there is a 
structurally similar negative control compound available. We 
believe that future work in this field should focus on the 
development of chemical probe toolsets, which fulfill these 
criteria.[7] This, in turn, will provide a better understanding of the 
human bromodomain family and may aid investigations into the 
role of broader epigenetic processes within human disease.  
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